Table 2. Genes most frequently published in AML expression studies.
Rank | Gene symbol | No. of references | No. of platforms | No. of differentially expressed features | Gene name |
1 | HOXB2 | 12 | 6 | 32 | homeobox B2 |
2 | PBX3 | 12 | 5 | 31 | pre-B-cell leukemia homeobox 3 |
3 | HOXA9 | 11 | 4 | 35 | homeobox A9 |
4 | POU4F1 | 11 | 3 | 29 | POU class 4 homeobox 1 |
5 | TSPAN7 | 10 | 5 | 16 | tetraspanin 7 |
6 | MYH11 | 10 | 3 | 38 | myosin, heavy chain 11, smooth muscle |
7 | RUNX1T1 | 10 | 3 | 34 | runt-related transcription factor 1; translocated to, 1 (cyclin D-related) |
8 | TRH | 10 | 3 | 21 | thyrotropin-releasing hormone |
9 | HLA-DPA1 | 10 | 3 | 20 | major histocompatibility complex, class II, DP alpha 1 |
10 | HOXB5 | 9 | 5 | 32 | homeobox B5 |
11 | SPARC | 9 | 5 | 16 | secreted protein, acidic, cysteine-rich (osteonectin) |
12 | HOXA10 | 9 | 4 | 34 | homeobox A10 |
13 | RNASE2 | 9 | 4 | 18 | ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) |
14 | CD34 | 9 | 3 | 16 | CD34 molecule |
15 | MEIS1 | 9 | 3 | 16 | Meis homeobox 1 |
16 | RUNX3 | 8 | 5 | 23 | runt-related transcription factor 3 |
17 | VCAN | 8 | 5 | 22 | versican proteoglycan |
18 | RBPMS | 8 | 4 | 21 | RNA binding protein with multiple splicing |
19 | HOXA4 | 8 | 4 | 18 | homeobox A4 |
20 | MN1 | 8 | 4 | 16 | meningioma (disrupted in balanced translocation) 1 |
21 | PRAME | 8 | 4 | 11 | preferentially expressed antigen in melanoma |
22 | JAG1 | 8 | 3 | 20 | jagged 1 (Alagille syndrome) |
23 | ITM2A | 8 | 3 | 18 | integral membrane protein 2A |
24 | RGS10 | 8 | 3 | 17 | regulator of G-protein signaling 10 |
25 | PGDS * | 8 | 2 | 12 | prostaglandin D2 synthase, hematopoietic |
The genes reported in at least eight independent studies are presented here. In order of preference, the genes are ranked by the number of independent studies, the number of unique platforms, and the total number of differentially expressed features.
*Gene symbol is not approved by HUGO Gene Nomenclature Committee.